Worldwide pharmacovigilance systems and tolrestat withdrawalFOPPIANO, M; LOMBARDO, G.Lancet (British edition). 1997, Vol 349, Num 9049, pp 399-400, issn 0140-6736Article

In vitro inhibition of glucose phosphorylation by an aldose-reductase inhibitor (Tolrestat) in some non-insulin-sensitive rabbit tissuesIANNELLO, S; CAVALERI, A; CAMUTO, M et al.Journal of diabetes and its complications. 1999, Vol 13, Num 2, pp 68-73, issn 1056-8727Article

Administration of ascorbic acid and an aldose reductase inhibitor (Tolrestat) in diabetes : Effect on urinary albumin excretionMCAULIFFE, A. V; BROOKS, B. A; FISHER, E. J et al.Nephron. 1998, Vol 80, Num 3, pp 277-284, issn 0028-2766Article

Effect of tolrestat, an aldose reductase inhibitor, on neutrophil respiratory burst activity in diabetic patientsIHM, S.-H; HYUNG JOON YOO; SUNG WOO PARK et al.Metabolism, clinical and experimental. 1997, Vol 46, Num 6, pp 634-638, issn 0026-0495Article

Impairment of afferent arteriolar myogenic responsiveness in the galactose-fed rat is prevented by tolrestatFORSTER, H. G; TER WEE, P. M; HOHMAN, T. C et al.Diabetologia (Berlin). 1996, Vol 39, Num 8, pp 907-914, issn 0012-186XArticle

YUA001, a novel aldose reductase inhibitor isolated from alkalophilic Corynebacterium sp. YUA25. I. Taxonomy, fermentation, isolation and characterizationBAHN, Y.-S; PARK, J.-M; BAI, D.-H et al.Journal of antibiotics (Tokyo. 1968). 1998, Vol 51, Num 10, pp 902-907, issn 0021-8820Article

Isolation of a non-covalent aldose reductase-nucleotide-inhibitor complexSUGIYAMA, K; ZHOU CHEN; LEE, Y. S et al.Biochemical pharmacology. 2000, Vol 59, Num 4, pp 329-336, issn 0006-2952Article

Impaired regeneration and no amelioration with aldose reductase inhibitor in crushed unmyelinated nerve fibers of diabetic ratsYASUDA, H; TERADA, M; TANIGUCHI, Y et al.Neuroreport (Oxford). 1999, Vol 10, Num 11, pp 2405-2409, issn 0959-4965Article

Pathogenesis of diabetic neuropathy: do hyperglycemia and aldose reductase inhibitors affect neuroactive steroid formation in the rat sciatic nerves?COLCIAGO, A; NEGRI-CESI, P; CELOTTI, F et al.Experimental and clinical endocrinology & diabetes. 2002, Vol 110, Num 1, pp 22-26, issn 0947-7349Article

Influence of tolrestat on the defective leukocyte-endothelial interaction in experimental diabetesCRUZ, J. W. M. C; OLIVEIRA, M. A; HOHMAN, T. C et al.European journal of pharmacology. 2000, Vol 391, Num 1-2, pp 163-174, issn 0014-2999Article

Molecular dynamics simulations of the structure of aldose reductase complexed with the inhibitor tolrestatRASTELLI, G; COSTANTINO, L.Bioorganic & medicinal chemistry letters (Print). 1998, Vol 8, Num 6, pp 641-646, issn 0960-894XArticle

Correlation of binding constants and molecular modelling of inhibitors in the active sites of aldose reductase and aldehyde reductaseCARBONE, Vincenzo; ZHAO, Hai-Tao; CHUNG, Roland et al.Bioorganic & medicinal chemistry. 2009, Vol 17, Num 3, pp 1244-1250, issn 0968-0896, 7 p.Article

Elevation of erythrocyte redox potential linked to galactonate biosynthesis : Elimination by TolrestatBERRY, G. T; WEHRLI, S; REYNOLDS, R et al.Metabolism, clinical and experimental. 1998, Vol 47, Num 11, pp 1423-1428, issn 0026-0495Article

Proceedings/Symposium on aldose reductase inhibition and late, complications of diabetes. International diabetes federation polyol pathway workshop, Madrid 23 September 1985WARD, J. D; BENFIELD, P. Ed.Drugs (Basel). 1986, Vol 32, issn 0012-6667, 55 p., suppl. 2Conference Proceedings

Design and synthesis of highly potent and selective (2-arylcarbamoyl-phenoxy)-acetic acid inhibitors of aldose reductase for treatment of chronic diabetic complicationsVAN ZANDT, Michael C; SIBLEY, Evelyn O; MITSCHLER, Andre et al.Bioorganic & medicinal chemistry. 2004, Vol 12, Num 21, pp 5661-5675, issn 0968-0896, 15 p.Article

Design and methods for a double-blind, randomized study of tolrestat for the prevention of nephropathy in normotensive patients with insulin-dependent diabetes mellitus and microalbuminuriaGRUNBERGER, G.Current therapeutic research. 1995, Vol 56, Num 4, pp 319-332, issn 0011-393XArticle

Diabetic-like retinopathy in rats prevented with an aldose reductase inhibitorROBISON, W. G. JR; NAGATA, M; LAVER, N et al.Investigative ophthalmology & visual science. 1989, Vol 30, Num 11, pp 2285-2292, issn 0146-0404Article

Human safety profile of tolrestat: an aldose reductase inhibitorRYDER, S; SAROKHAN, B; SHAND, D. G et al.Drug development research. 1987, Vol 11, Num 2, pp 131-143, issn 0272-4391Article

Effect of tolrestat on red blood cell sorbitol levels in patients with diabetesRASKIN, P; ROSENSTOCK, J; CHALLIS, P et al.Clinical pharmacology and therapeutics. 1985, Vol 38, Num 6, pp 625-630, issn 0009-9236Article

Metabolic disposition and pharmacokinetics of the aldose reductase inhibitor tolrestat in rats, dogs, and monkeysCAYEN, M. N; HICKS, D. R; FERDINANDI, E. S et al.Drug metabolism and disposition. 1985, Vol 13, Num 4, pp 412-419, issn 0090-9556Article

Tolrestat kineticsHICKS, D. R; KRAML, M; CAYEN, M. N et al.Clinical pharmacology and therapeutics. 1984, Vol 36, Num 4, pp 493-499, issn 0009-9236Article

Acetic Acid Aldose Reductase Inhibitors Bearing a Five-Membered Heterocyclic Core with Potent Topical Activity in a Visual Impairment Rat ModelLA MOTTA, Concettina; SARTINI, Stefania; SALERNO, Silvia et al.Journal of medicinal chemistry (Print). 2008, Vol 51, Num 11, pp 3182-3193, issn 0022-2623, 12 p.Article

Inhibition of 3(17)α-hydroxysteroid dehydrogenase (AKR1C21) by aldose reductase inhibitorsDHAGAT, Urmi; ENDO, Satoshi; HARA, Akira et al.Bioorganic & medicinal chemistry. 2008, Vol 16, Num 6, pp 3245-3254, issn 0968-0896, 10 p.Article

Effect of treatment with an aldose-reductase inhibitor on symptomatic carpal tunnel syndrome in Type 2 diabetesMONGE, L; DE MATTEI, M; DANI, F et al.Diabetic medicine. 1995, Vol 12, Num 12, pp 1097-1101, issn 0742-3071Article

Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetesVAN GRIENSVEN, J. M. T; JUSKO, W. J; LEMKES, H. H. P. J et al.Clinical pharmacology and therapeutics. 1995, Vol 58, Num 6, pp 631-640, issn 0009-9236Article